Perceptions and Experiences ofAbemaciclib and Endocrine TherapY (PEATY)
Chief Investigator: Professor Dame Lesley Fallowfield
Researcher: Dr Helena Harder
This study is looking at the expectations and experiences of women who are taking abemaciclib and hormone therapy for early breast cancer. Abemaciclib is a targeted therapy. Targeted cancer drugs are treatments that help the body to control the growth and spread of cancer. These drugs focus on specific abnormalities within cancer cells that allow them to survive. When used to treat breast cancer, abemaciclib is taken together with hormone therapy (also called endocrine therapy).
Treatment with abemaciclib and hormone therapy is relatively new and little is known about people’s expectations of this treatment, their experiences, and how they manage possible side effects. We know that diarrhoea is a very common side effect of abemaciclib, and can be severe for some people. Finding out more about people’s experiences and understanding their needs, is essential if we want to be able to best inform and support them.
PEATY will recruit 25 to 30 women and invite them to take part in a series of three interviews. Our research team will interview women before or shortly after they have started treatment. This is to find out what their treatment expectations are, and what they know about the drugs they are prescribed. Follow-up interviews will be conducted approximately 4 and 8 weeks later to find out more about their experiences. We would like to know if they have experienced side effects during the first weeks of treatment . We would be particularly interested to hear if they experienced diarrhoea, what steps they may have taken to reduce this, and whether it was successful. We will also ask about side effects related to hormone therapy (for example joint pain, hot flushes or fatigue), and talk about the impact of the treatment on their lives, and how they and their doctors have tried to manage any problems.
We hope that the results of the study can be used to develop materials to help healthcare professionals communicate the effects of treatment.